Neurotech inks European development deal for cannabinoid therapies

Neurotech enters partnership agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company.

Neurotech has inked a development deal in Europe. Pic: Getty Images.

• Neurotech enters partnership agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company

• Development agreement to enable Neurotech to expand into new markets

• Neurotech looks to scale production to meet future product demand upon regulatory approvals

 

Special Report: Neurotech International has inked a deal with a European leader in development and scale up of cannabis-based products for pharmaceutical use as it eyes Australian regulatory approval for its broad-spectrum cannabinoid drug NTI164.

Neurotech International (ASX:NTI), a clinical-stage biopharmaceutical focused predominantly on paediatric neurological disorders, has signed a binding development agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis  Company (ECC).

RH Pharma is a pharmaceutical company based in Skopje, North Macedonia, specialising in the cultivation and production of medical cannabis products with, noted Neurotech, its operations conducted in compliance with EU Good Manufacturing Practice standards.

The initial term includes an upfront payment of €25,000 (A$41,400) from Neurotech with additional services to be provided, as requested by Neurotech, over a period of 12 months.

Neurotech noted that ECC is one of Europe’s most advanced and established providers of cannabis-based pharmaceutical products and a trusted partner for brands seeking to expand into international markets.

The aim of this deal, said NTI, is to generate a strain-agnostic, pharmaceutical-grade broad-spectrum cannabinoid drug product suitable for paediatric patients with neurodevelopmental disorders based on RH Pharma’s proprietary CO2 extraction technology.

Neurotech said the deal aligns with its proprietary composition and formulation consisting of certain cannabinoids at specific concentrations that has demonstrated significant improvement in patients with progressive neuroinflammatory disorders including autism, Rett Syndrome, and PANDAS/PANS.

The company added that the development agreement would enable the biopharmaceutical company to expand into new markets while ensuring production at the highest pharmaceutical standards.

Strong clinical pipeline

Neurotech has several clinical programs underway with NTI164 and has successfully completed a phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD).

The company has completed and reported statistically significant and clinically meaningful phase I/II trial results in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS.

It has also successfully completed a phase I/II trial in Rett Syndrome and received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

Scaling production to meet future demand

Dr Anthony Filippis, CEO and managing director of Neurotech International, said the company was delighted to partner with ECC, which is renowned for its expertise in cannabis product development.

“As we accelerate our plans for registration of NTI64 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approval(s),” he said.

“Our commitment to regulatory compliance and quality is further strengthened by collaborations with leading medical institutions and key clinicians, reinforcing our position within the industry.

“This agreement not only accelerates our global growth strategy but also ensures we can deliver premium-quality products with unparalleled consistency and scalability, independent of strain-specific limitations.”

ECC general manager Rebeka Levy meanwhile said the company was thrilled to collaborate with Neurotech.

“Our shared vision for innovation and international expansion positions us to deliver exceptional products to meet growing global demand,” Levy said.

“The development agreement aligns with the company’s focus on innovation and making a meaningful difference in the lives of those affected by neurological disorders.”

This article was developed in collaboration with Neurotech International, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as Neurotech inks European development deal for cannabinoid therapies